Tamer Lamle Ph.D.

Corporate Development and M&A Professional

Basel, Switzerland


Highly experienced ex-M&A banker with a uniquely broad background covering in-house M&A/corporate development and business development & licensing. Sector agnostic although industry focus more recently within the pharmaceuticals, biotech and life sciences sector with further significant experience across the chemicals and broader industrials sectors. Currently based in Basel, Switzerland, but fully mobile and available on remote and/or hybrid basis. Career highlights: ▪ Significant Corporate Finance/M&A experience gained at boutique and bulge bracket institutions in London (Merrill Lynch, William Blair & HSBC) and a deep understanding of the pharmaceuticals industry gained through roles at Roche IR and Swedish Orphan Biovitrum (Sobi) BD&L in Switzerland ▪ As Director, Corporate Development at Sobi, I led several complex DD processes, while supporting and cultivating Board-level decisions and business strategy, during a period of intense activity and strong growth (2019-2021). Sobi deal highlights (Immunology/Hematology): − Novimmune acquisition (Jul 2019) - led confirmatory DD liaising directly with management − Apellis ex-US partnership (Oct 2020) - led commercial & financial DD ▪ Experienced Investor Relations Officer involved in all aspects of IR-related activities at Roche − Public spokesperson and relationship manager to specialist investors − M&A deals: IR lead/core deal team member for high profile M&A transactions e.g. InterMune, FMI − Sustainability investment growth: Oversaw a significant increase in investments since 2013 (c.3bn USD) elevating Roche to the most widely held stock worldwide in terms of dedicated Socially Responsible Investing (SRI) funds − Led special projects (for CFO office) also supporting the Corporate Executive Committee (CEC) Relevant experience: Strategic ▪ Pharma/Biotech: Deep industry experience fostered across IR and Corporate Development in roles requiring C-suite level interactions with projects focused on issues and challenges management face. Exposure ranges from an external spokesperson for Roche cultivating the equity story to specialist investors and developing business cases to support company strategy in BD ▪ Corporate finance/M&A (Healthcare/Chemicals): Focus on client strategic advisory work including developing strategies to enhance shareholder value post financial crisis Corporate Finance & Analytics ▪ Strong analytical & financial skills developed over ten years in financial services and pharmaceuticals − Valuation modelling & forecasting; Search & evaluation; Market research and analysis ▪ Broad spectrum of experience across investment banking services − M&A deal generation (business development) to execution and close (live transactions, due diligence processes); Strategic advisory projects; Debt financing; Equity capital markets ▪ Experienced IR professional across all key elements of the function e.g. M&A and fixed income lead; Quarterly earnings coordinator; Responsible for CEC management presentations and briefings Leadership ▪ Demonstrated ability to lead and collaborate across a wide variety of internal, up to senior management, and external stakeholders, leading and driving projects through to completion − Strategic advisory work for M&A clients facilitating Board-level decisions (Merrill Lynch, HSBC) − Lead and support in a diverse range of cross-functional strategic projects ranging from Roche CFO and Sobi CEO offices to investor-related activities (e.g. IR events, roadshows, M&A) − Experienced finance business partner and leader building internal network across a multitude of global functions at Sobi & Roche and significant experience of influencing without authority External/Internal Stakeholder Management ▪ Public spokesperson for the world's largest biotech (Roche) – primary contact to specialist investors ▪ Demonstrated ability in collaborating cross-functionally (across global/commercial functions) and with management to meet external deliverables – DD processes, live deals, IR presentations, congresses & investor roadshows ▪ Experience presenting to a wide variety of audiences both internal and external, incl. management

Domain experience

Relevant Total Experience: 15 years

Seniority Level: Senior

Sector Experience: 

Chemicals Commercial and Professional Services Pharmaceuticals, Biotechnology and Life Sciences


Skilled in: Sell-side M&A, Corporate Development

Technical Skills: Microsoft Excel, PowerPoint, Bloomberg, Microsoft Office

Languages: English

Work Experience

Sobi - Swedish Orphan Biovitrum (Basel, Switzerland)

Director, Corporate Development



- 01/05/2021

Director, Business Development & Licensing and Strategic Projects (CEO Office) at Swedish Orphan Biovitrum (Sobi) supporting and cultivating Board-level decisions and business strategy during a period of intense activity and strong growth. Sobi deal summary (Immunology/Haeme): − Novimmune acquisition (Jul 2019) - led confirmatory DD liaising directly with management − Apellis ex-US partnership (Oct 2020) - led commercial & financial DD Highlights: ▪ Leading and supporting a broad set of strategic projects driven by the CEO office related to Board-level strategic plans through to developing the equity story ▪ Closed two material deals (Immunology/Haematology franchises) since joining ▪ Acted as BD lead in multiple live BD&L processes while also developing investment cases, including valuation, for potential strategic opportunities

F. Hoffmann-La Roche (Basel, Switzerland)

Investor Relations Officer



- 01/01/2019

▪ Public spokesperson and primary contact to specialist investors ▪ Managed strategic IR/finance projects and led special projects for CFO. Also supported Executive Committee producing presentations around strategic initiatives and IR-related activities from developing strategic rationale re M&A and debt financing for investors to quantitative analyses ▪ Lead and project manager for all key quarterly earnings deliverables including management presentations, consensus estimates and briefing materials ▪ Lead and support in developing content and preparing presentations for investor events (e.g. medical congresses, M&A deals, IR events & roadshows) and CEC management briefings

HSBC Global Banking and Markets (London)

M&A Senior Associate



- 01/01/2012

Senior member of the global chemicals M&A/investment banking team. Focus on Asian & Middle Eastern petrochemical and European specialty chemicals clients. ▪ Successfully delivered projects assessing strategic options for global public clients, as well as project managing business development pitches to potential new clients

Merrill Lynch (London)

M&A Associate



- 01/04/2011

M&A Associate – Joined as an Analyst ▪ Associate member & Analyst team leader for market leading global healthcare/chemicals M&A team ▪ Post promotion undertook project leadership responsibilities, reporting directly to senior stakeholders (MDs/Directors) whilst providing leadership to Analysts and interns


University of Cambridge




- 01/09/2006

Ph.D. Thesis: Controlling surface topography and chemistry of polymer films Commercial sponsor: DuPont Highly interdisciplinary PhD with research spanning The Nanoscience Centre and The Melville Laboratory for Polymer Synthesis at the University of Cambridge Chemistry Department.

King's College London, U. of London




- 01/09/2001